OKYO Pharma Limited (OKYO)
Market Cap | 52.90M |
Revenue (ttm) | n/a |
Net Income (ttm) | -6.70M |
Shares Out | 21.77M |
EPS (ttm) | -0.01 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,741 |
Open | 2.21 |
Previous Close | 2.32 |
Day's Range | 2.21 - 2.43 |
52-Week Range | 1.61 - 6.11 |
Beta | 0.02 |
Analysts | Buy |
Price Target | 3.50 (+44.03%) |
Earnings Date | n/a |
About OKYO
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OKYO stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 44.03% from the latest price.
News

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022
LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DE...

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-

OKYO to Participate at Biotech Showcase
LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye di...

OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye di...

OKYO Pharma Limited - Change of Auditor
LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye di...

OKYO Pharma Limited – PDMR dealing
LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye dise...

OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-

OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
Monday, November 14 th @ 8 am ET, registration details below

OKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference
New York, New York--(Newsfile Corp. - October 20, 2022) - OKYO Pharma Ltd. (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to ad...

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat inf...

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
NEW YORK, NY / ACCESSWIRE / September 8 2022 / OKYO Pharma Limited (NASDAQ:OKYO); (LSE:OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory ...

OKYO Pharma Limited: Result of Annual General Meeting
LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approa...

OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
LONDON & NEW YORK & NORTH AUGUSTA, S.C.--(BUSINESS WIRE)-- #DryEye--OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules t...

OKYO Pharma Limited - Final audited results for the year ended 31 March 2022
LONDON and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2022.